Antiproteinuric effects of @entity4688 and XXXX : a pilot study.

@entity1 @entity644 @entity4688 @entity8 @entity1289 @entity9886 @entity972 @entity1011
In this randomized double-blind crossover trial we compared the antiproteinuric effects of @entity4688 and @entity9886 in six @entity1 with @entity644 and underlying @entity8 . The primary endpoint was reduction in @entity644 during therapy. The study had two 8-week on-drug arms, with a 4-week washout period between. Baseline @entity644 was similar, @entity4688 87 mg/m(2) per hour and @entity9886 77 mg/m(2) per hour. The mean reduction in @entity644 with @entity4688 was 48% (37%-57%) with a standard error of the mean of 3%; with @entity9886 it was 31% (14%-52%) with a standard error of the mean of 7%. Although there was a significant reduction in @entity644 with the use of both drugs, the difference in reduction of @entity644 , 48% versus 31%, was not considered clinically significant. @entity972 remained below 4.5 mmol/l in all @entity1 . No @entity1 's @entity1011 rose more than the standard deviation of our assay. Blood pressure (BP) control was acceptable in four of the six @entity1 ; two @entity1 had persistently elevated or increased BP on each drug. Side effects were minimal; none requiring withdrawal, one requiring dose reduction. Studies have shown that @entity1289 inhibitors can reduce @entity644 in @entity1 with @entity8 . No studies to date have examined the reduction of @entity644 achieved by angiotensin receptor blockers. Our study, although small, suggests that angiotensin receptor blockers may reduce @entity644 as effectively, and as safely, as @entity1289 inhibitors.
